Gonadotropin-releasing hormone analogue treatment for precocious puberty. Twenty years of experience

Endocr Dev. 2005;8:94-125. doi: 10.1159/000084097.

Abstract

Central precocious puberty (CPP) is the premature onset of puberty due to a precocious activation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. This condition results in accelerated development of secondary sex characteristics, accelerated bone maturation, impaired final height with disproportioned body appearance and can have a disturbing impact on the psychosocial behavior of children suffering from CPP. It is therefore necessary to assess the hormonal status of children who show pubertal signs before the age 8 years in girls and 9 years in boys. The indication for treatment should be made after evaluating pubertal progression, progression of bone age maturation and final height prognosis, development of reproductive function, and psychosocial adjustment and well-being. This paper summarizes the experience of GnRH agonist treatment, which is momentarily the treatment of choice for central precocious puberty in children.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Body Size
  • Child
  • Female
  • Gonadotropin-Releasing Hormone / analysis
  • Gonadotropin-Releasing Hormone / physiology*
  • Humans
  • Hypothalamus / physiology
  • Male
  • Psychology
  • Puberty / physiology
  • Puberty, Precocious / diagnosis*
  • Puberty, Precocious / physiopathology
  • Puberty, Precocious / psychology
  • Puberty, Precocious / therapy*
  • Sexual Maturation / physiology
  • Treatment Outcome

Substances

  • Gonadotropin-Releasing Hormone